Skip to content

Harmony Biosciences Holdings, Inc.

HRMY · XNAS

CIK 1802665fmd_0EY7KD0RD4M1DKY3KGD1PEJQARManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2019 to Sep 30, 2026, 29 periods

Latest annual · FY2025

Millions
Total revenues
868
Gross profit
670
Operating income
208
Net income
159
Free cash flow
348

Latest quarter · Q3 FY2026

Millions
Total revenues
269
Gross profit
188
Operating income
54
Net income
48

Daily close · HRMYIEX trades only

Nov 13, 2025 to Nov 11, 2026 · 250 sessions

34.23 USD

2530354045Nov 13, 2025May 14, 2026Nov 11, 2026Vol

Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.

Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms

Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2022 to FY2025
+25.6%
Revenue, 5 yearsFY2020 to FY2025
+40.3%
Net income, 5 yearsFY2020 to FY2025
n/m

Harmony Biosciences Holdings, Inc. (HRMY) financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2025FY2024ChangeSource
Revenue$868.5 million$714.7 million+21.5%10-K 2026-02-24 · proof
Gross profit$670.1 million$557.9 million+20.1%10-K 2026-02-24 · proof
Operating income$208.5 million$190.8 million+9.2%10-K 2026-02-24 · proof
Net income$158.7 million$145.5 million+9.1%10-K 2026-02-24 · proof
Cash from operating activities$348.2 million$219.8 million+58.4%10-K 2026-02-24 · proof
Free cash flow$347.9 million$218.7 million+59.1%10-K 2026-02-24 · proof
Total assets$1.3 billion$999.2 million+27.3%10-K 2026-02-24 · proof
Total liabilities$401.4 million$340 million+18%10-K 2026-02-24 · proof
Cash and cash equivalents$752.5 million$453 million+66.1%10-K 2026-02-24 · proof
Total debt$163.7 million$179.3 million-8.7%10-K 2026-02-24 · proof
What was Harmony Biosciences Holdings, Inc. (HRMY)'s revenue in fiscal 2025?
Harmony Biosciences Holdings, Inc. (HRMY) reported revenue of $868.5 million for fiscal 2025 (the year ended Dec 31, 2025), against $714.7 million the year before (+21.5%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
What was Harmony Biosciences Holdings, Inc. (HRMY)'s gross profit in fiscal 2025?
Harmony Biosciences Holdings, Inc. (HRMY) reported gross profit of $670.1 million for fiscal 2025 (the year ended Dec 31, 2025), against $557.9 million the year before (+20.1%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
What was Harmony Biosciences Holdings, Inc. (HRMY)'s operating income in fiscal 2025?
Harmony Biosciences Holdings, Inc. (HRMY) reported operating income of $208.5 million for fiscal 2025 (the year ended Dec 31, 2025), against $190.8 million the year before (+9.2%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
What was Harmony Biosciences Holdings, Inc. (HRMY)'s net income in fiscal 2025?
Harmony Biosciences Holdings, Inc. (HRMY) reported net income of $158.7 million for fiscal 2025 (the year ended Dec 31, 2025), against $145.5 million the year before (+9.1%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
What was Harmony Biosciences Holdings, Inc. (HRMY)'s cash from operating activities in fiscal 2025?
Harmony Biosciences Holdings, Inc. (HRMY) reported cash from operating activities of $348.2 million for fiscal 2025 (the year ended Dec 31, 2025), against $219.8 million the year before (+58.4%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
What was Harmony Biosciences Holdings, Inc. (HRMY)'s free cash flow in fiscal 2025?
Harmony Biosciences Holdings, Inc. (HRMY) reported free cash flow of $347.9 million for fiscal 2025 (the year ended Dec 31, 2025), against $218.7 million the year before (+59.1%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
What are Harmony Biosciences Holdings, Inc. (HRMY)'s total assets?
As of Dec 31, 2025, Harmony Biosciences Holdings, Inc. (HRMY) reported total assets of $1.3 billion, against $999.2 million a year earlier (+27.3%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
What are Harmony Biosciences Holdings, Inc. (HRMY)'s total liabilities?
As of Dec 31, 2025, Harmony Biosciences Holdings, Inc. (HRMY) reported total liabilities of $401.4 million, against $340 million a year earlier (+18%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
What are Harmony Biosciences Holdings, Inc. (HRMY)'s cash and cash equivalents?
As of Dec 31, 2025, Harmony Biosciences Holdings, Inc. (HRMY) reported cash and cash equivalents of $752.5 million, against $453 million a year earlier (+66.1%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
What is Harmony Biosciences Holdings, Inc. (HRMY)'s total debt?
As of Dec 31, 2025, Harmony Biosciences Holdings, Inc. (HRMY) reported total debt of $163.7 million, against $179.3 million a year earlier (-8.7%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:HRMY&period_type=annual&limit=5"

Information only, not investment advice.